Effects of rosiglitazone maleate when added to a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate renal impairment: A post hoc analysis

Agrawal, Ajai; Sautter, M.; Jones, Nigel C.

doi:10.1016/s0149-2918(03)80331-4

Cited by 21 publications

(16 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rosiglitazone was effective and well tolerated in this population, with no obvious differences with results observed in patients with normal kidney function 115 . In two other studies, rosiglitazone was well tolerated and beneficial in patients with T2DM on peritoneal dialysis therapy 116 or undergoing regular hemodialysis 117 .…”

Section: Rosiglitazonementioning

confidence: 62%

Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease

Scheen¹

2013

Expert Opinion on Drug Metabolism & Toxicology

View full text Add to dashboard Cite

SUMMARYIntroduction : People with chronic kidney disease (CKD) of stages 3-5 (creatinine clearance < 60 ml/min) represent 25-30% of patients with type 2 diabetes (T2DM), but the problem is underrecognized or neglected in clinical practice. However, most oral antidiabetic agents have limitations in case of renal impairment, either because they require a dose adjustment or because they are contraindicated for safety reasons. Expert Opinion : Because of potential important PK interferences and for safety reasons, the pharmacological management of T2DM should be adjusted according to kidney function. In general, the daily dose should be reduced according to glomerular filtration rate (GFR) or even the drug is contraindicated in presence of more severe CKD. This is the case for metformin (risk of lactic acidosis) and for many sulfonylureas (risk of hypoglycemia). At present, however, the exact GFR cutoff for metformin use is controversial. New antidiabetic agents are better tolerated in case of CKD, although clinical experience remains quite limited for most of them. The dose of DPP-4 inhibitors should be reduced (except for linaglitpin) whereas both the efficacy and safety of SGLT2 inhibitors are questionable in presence of CKD.

show abstract

Section: Rosiglitazonementioning

confidence: 62%

Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease

Scheen¹

2013

Expert Opinion on Drug Metabolism & Toxicology

View full text Add to dashboard Cite

show abstract

“…In patients with advanced diabetic nephropathy, pioglitazone therapy produced a similar number of serious adverse events in comparison with those observed in patients treated with glipizide (78). Finally, combined therapy with rosiglitazone and SU was well tolerated in a group of 301 type 2 diabetic patients with mild to moderate CRF inadequately controlled with monotherapy (83).…”

Section: Tolerance and Safety Profile Of Pparg Agonists In Crfmentioning

confidence: 65%

“…Moreover, agonists would maintain their efficacy on glycaemic control regardless of the presence or absence of CRF. Agrawal et al (83) studied the effects of the addition of rosiglitazone to a SU (glyburide, gliclazide and glipizide) treatment regimen for 6 months, in patients with type 2 diabetes mellitus with mild to moderate renal impairment inadequately controlled by SU monotherapy. Results showed similar efficacy in patients with normal renal function, and in patients with mild to moderate renal impairment (83).…”

Section: Chronic Renal Insufficiencymentioning

confidence: 99%

Peroxisome proliferator-activated receptor gamma agonists in renal disease

Iglesias

Díez

2006

eur j endocrinol

View full text Add to dashboard Cite

Type 2 diabetes is a well recognised cause of chronic renal failure (CRF). Only few oral antidiabetic drugs can be used for treating type 2 diabetes in patients with CRF. Among them are repaglinide, a rapid-acting prandial insulin releaser, and peroxisome proliferator-activated receptor gamma (PPARg) agonists, such as rosiglitazone and pioglitazone. These compounds are metabolised in the liver, therefore accumulation of the drug and the risk of severe and prolonged hypoglycaemia are minimised. PPARg receptors are expressed in many tissues including the kidney. Recently, numerous healthful effects of PPARg agonists on several aspects related to renal function have been increasingly reported. These drugs have shown to possess many advantageous anti-inflammatory, haemodynamic, vascular and metabolic effects. In the present paper we have reviewed the more recent experimental studies that evaluated these potential beneficial effects of PPARg agonists on renal function and revised the results of their utilisation in patients with different degrees of renal impairment, in dialysis patients, and in patients with diabetes mellitus after kidney transplantation. Finally, tolerability and safety profile of PPARg agonists in patients with reduced glomerular filtration rate are also analysed. European Journal of Endocrinology 154 613-621

show abstract

“…Rosiglitazone use among patients with impaired renal function (creatinine clearance 30-80 ml/min) [39] produced similar effects on A1c compared to patients without renal impairment. In a retrospective chart review of patients on dialysis with end stage renal disease, rosiglitazone was associated with weight gain and a decrease in hematocrit at 3-month follow-up, compared to [69].…”

Section: Type 2 Diabetesmentioning

confidence: 90%

Comparative Effectiveness of Pioglitazone and Rosiglitazone in Type 2 Diabetes, Prediabetes,and the Metabolic Syndrome: A Meta-Analysis

Norris

Carson

Roberts

2007

CDR

View full text Add to dashboard Cite

Objective -To assess the comparative efficacy and safety of pioglitazone and rosiglitazone.Research design and methods -Multiple electronic databases were searched for randomized, controlled trials (RCTs) of efficacy or effectiveness and for studies of any design which reported adverse events. Pooled estimates were calculated using a random effects model.Results -Eighty-seven RCTs fulfilled our inclusion criteria for efficacy or effectiveness and 42 studies examined safety or tolerability. Two head-to-head RCTs of type 2 diabetes demonstrated significant improvements in A1c in both groups at follow-up with no significant difference between groups; a third study found no significant change in A1c in either group. The pooled estimate of effect on A1c for pioglitazone compared to placebo was -0.99% (95% confidence interval [CI], -1.18, -0.81) and for rosiglitazone was -0.92% (95% CI, -1.2, -0.64). Indirect comparison revealed no significant difference in A1c (between-drug difference -0.07% [95% CI, -0.41, 0.27]). Rosiglitazone increased total cholesterol compared to pioglitazone (net between-drug effect 13.91 mg/dl [95% CI, 1.20 to 26.62]). Both drugs increased weight by 2 to 3 kg and rates of adverse events were similar for the two drugs. Data were insufficient to assess comparative effects on health outcomes such as cardiovascular events.Conclusions -Based largely on indirect evidence, the two thiazolidinediones appear to have similar effects on glycemic control and similar side-effect profiles. Rosiglitazone may increase total cholesterol compared to pioglitazone. Studies are needed which provide direct comparisons between the two drugs, particularly for long-term health outcomes.

show abstract

Effects of rosiglitazone maleate when added to a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate renal impairment: A post hoc analysis

Cited by 21 publications

References 16 publications

Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease

Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease

Peroxisome proliferator-activated receptor gamma agonists in renal disease

Comparative Effectiveness of Pioglitazone and Rosiglitazone in Type 2 Diabetes, Prediabetes,and the Metabolic Syndrome: A Meta-Analysis

Contact Info

Product

Resources

About